Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 43 entries
View as:

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

Phase: N/A Priority: Normal
NCT ID: NCT02381808 Org: User:
Start: 12/31/14 End: 12/31/18 Due: 12/31/19

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01724801 Org: User:
Start: 10/14/12 End: 09/14/16 Due: 09/14/17

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04988607 Org: User:
Start: 08/31/21 End: 05/31/25 Due: 05/31/26

Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02985203 Org: User:
Start: 11/30/16 End: 04/30/18 Due: 04/30/19

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03768037 Org: User:
Start: 11/26/18 End: 11/26/20 Due: 11/26/21

Phase II Umbrella Study Directed by Next Generation Sequencing

Phase: N/A Priority: Normal
NCT ID: NCT03574402 Org: User:
Start: 07/09/18 End: 12/30/24 Due: 12/30/25

Efficacy and Safety of Camrelizumab in Real-World Study

Phase: N/A Priority: Normal
NCT ID: NCT04631146 Org: User:
Start: 11/30/20 End: 12/30/21 Due: 12/30/22

A Non-interventional Retrospective Study on Overall Survival in Completely Resected Chinese NSCLC Patients With Adenocarcinoma Histology- ICAN Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03658928 Org: User:
Start: 08/31/18 End: 04/30/19 Due: 04/30/20

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02348450 Org: User:
Start: 02/28/15 End: 12/31/18 Due: 12/31/19

PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT03029858 Org: User:
Start: 01/31/17 End: 09/30/20 Due: 09/30/21

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02759614 Org: User:
Start: 04/01/16 End: 06/01/19 Due: 06/01/20

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Phase: N/A Priority: Normal
NCT ID: NCT04841811 Org: User:
Start: 06/20/22 End: 12/31/26 Due: 12/31/27

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06092086 Org: User:
Start: 08/18/23 End: 08/01/30 Due: 08/01/31

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01405079 Org: User:
Start: 09/19/11 End: 12/31/20 Due: 12/31/21

A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04306042 Org: User:
Start: 03/31/20 End: 12/31/22 Due: 12/31/23

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Phase: N/A Priority: Normal
NCT ID: NCT04575415 Org: User:
Start: 10/07/20 End: 12/31/23 Due: 12/31/24

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD

Phase: N/A Priority: Normal
NCT ID: NCT05457049 Org: User:
Start: 08/01/22 End: 08/01/25 Due: 08/01/26

The Impact of Neurocognitive Function in Patients With Multiple Brain Metastases Receiving Whole Brain Radiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03626818 Org: User:
Start: 08/31/18 End: 06/30/21 Due: 06/30/22

Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02171325 Org: User:
Start: 06/30/14 End: 06/30/21 Due: 06/30/22

Third-line Treatment of Gefitinib in NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT01933347 Org: User:
Start: 04/07/14 End: 04/10/18 Due: 04/10/19

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Phase: N/A Priority: Normal
NCT ID: NCT02725918 Org: User:
Start: 04/01/16 End: 02/28/21 Due: 02/28/22

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Phase: N/A Priority: Normal
NCT ID: NCT04793139 Org: User:
Start: 04/01/21 End: 12/30/24 Due: 12/30/25

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04252365 Org: User:
Start: 03/01/20 End: 12/01/21 Due: 12/01/22

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02095782 Org: User:
Start: 03/31/14 End: 01/20/17 Due: 01/20/18

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03046316 Org: User:
Start: 06/01/20 End: 07/01/26 Due: 07/01/27